81 results on '"Gasparetto, Cristina"'
Search Results
2. Acceptance and Commitment Therapy May Improve Physical Function after Allogeneic Hematopoietic Stem Cell Transplant
3. P-285 Real-world clinical outcomes and treatment patterns among patients with triple-class exposed multiple myeloma: an analysis using the Connectmultiple myeloma disease registry
4. OA-29 First results from the randomized portion of a phase 2 study of venetoclax plus carfilzomib-dexamethasone vs carfilzomib-dexamethasone in patients with t(11;14) relapsed/refractory multiple myeloma
5. P-396 Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed/refractory multiple myeloma
6. A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial
7. Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
8. Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry
9. Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) and Lenalidomide (R) Maintenance to Progression in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
10. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease
11. P-229: Real-world outcomes of sequencing elotuzumab (elo)-based regimens following daratumumab (dara) in patients with relapsed/refractory multiple myeloma: results from the Connect® MM Registry
12. P-195: Lenalidomide, bortezomib, and dexamethasone (RVd) as first-line (1L) therapy in patients who are non-transplanted: results from the Connect® MM registry
13. Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years
14. Home-Based Hematopoietic Cell Transplantation in the United States
15. Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) with Omidubicel: Long-Term Follow-up from a Single Center
16. Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry
17. A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
18. OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)
19. P-136: Health-related quality of life (HRQL) among real-world Ide-Cel–eligible patients (pts) with relapsed/refractory Multiple Myeloma (RRMM): results from the Connect® MM registry
20. MM-392: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
21. Poster: MM-392: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
22. MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)
23. Poster: MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)
24. Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation
25. Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies
26. Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation
27. A Phase 1 Study of the Safety and Feasibility of Improving Cardiorespiratory Fitness through a Remotely Monitored, Mobile Health Supported High Intensity Interval Training Program (REMM-HIIT)
28. Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients
29. Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients
30. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
31. Clinical and Neuroimaging Correlates of Post-Transplant Delirium
32. Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry
33. Cognitive Impairment in Candidates for Allogeneic Hematopoietic Stem Cell Transplantation
34. Clinical and Neuroimaging Predictors of Post-Transplant Delirium
35. Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT
36. A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
37. Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
38. Frequency of and Associations Amongst Baseline Cytogenetics in Patients With Newly Diagnosed Multiple Myeloma in the Connect® MM Registry
39. Effect of t(11;14) on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect® MM Registry
40. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
41. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma
42. Phase I, Dose Escalation Study of Naïve T-Cell Depleted Donor Lymphocyte Infusion Following Allogeneic Stem Cell Transplantation
43. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade
44. Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)
45. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry
46. Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning
47. Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma
48. Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization
49. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (“VCD-Lite”) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma
50. Trends in Survival Outcomes Among Patients (pts) Relapsing Early after Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) (CIBMTR Study # MM14-03)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.